Back to top
more

VAREX IMAGING (VREX)

(Real Time Quote from BATS)

$9.30 USD

9.30
315,064

+1.49 (19.08%)

Updated Aug 8, 2025 10:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Boston Scientific (BSX) New Buyouts Aid Amid COVID Resurgence

by Zacks Equity Research

Boston Scientific's (BSX) new acquisitions like Preventice, Farapulse and Lumenis Surgical, which closed in March, August and September of 2021, respectively, are contributing to its inorganic growth.

Zacks Equity Research

Alcon (ALC) on Track With Successful Global PRECISION1 Rollout

by Zacks Equity Research

Alcon (ALC) enhances contact lens experience, especially for new wearers, with the continued successful rollout of PRECISION1.

Zacks Equity Research

Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Robust performance of the base business and COVID-19 testing volume gains are driving the top line for Quest Diagnostics (DGX).

Zacks Equity Research

CVS Health (CVS) Scales a 52-Week High: What's Driving It?

by Zacks Equity Research

Robust performance by the Pharmacy Services and Health Care Benefits arms is driving the top line for CVS Health (CVS).

Zacks Equity Research

Hologic (HOLX) Reports New Findings on Breast Cancer Index

by Zacks Equity Research

Hologic's (HOLX) latest data on Breast Cancer Index demonstrates its effectiveness in predicting net benefit from extended endocrine therapy.

Zacks Equity Research

Here's Why You Should Hold on to Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.

Zacks Equity Research

Thermo Fisher (TMO) Completes Acquisition of Leading CRO

by Zacks Equity Research

Thermo Fisher's (TMO) acquisition of PPD is likely to bolster its Laboratory Products and Services arm.

Zacks Equity Research

NextGen's (NXGN) Integrated Platform Gets Adopted by Monmouth

by Zacks Equity Research

NextGen's (NXGN) comprehensive solution suite was adopted by Monmouth to better cater to patients' medical and dental needs.

Zacks Equity Research

QIAGEN (QGEN) Gets CE Mark for QuantiFERON SARS-CoV-2 Assay

by Zacks Equity Research

QIAGEN's (QGEN) QuantiFERON SARS-CoV-2 assay enables a comprehensive assessment of immunity developed by COVID-19 vaccines.

Zacks Equity Research

Change Healthcare (CHNG) Cloud-Native PACS Now in Clinical Use

by Zacks Equity Research

The clinical use of Change Healthcare's (CHNG) cloud-native Stratus Imaging PACS is likely to enhance radiologists' productivity.

Zacks Equity Research

Here's Why You Should Retain IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investors are optimistic about IDEXX's (IDXX) better-than-expected results and continued international growth in the third quarter.

Zacks Equity Research

Bruker (BRKR) Assay to Offer Reliable Omicron Variant Detection

by Zacks Equity Research

Bruker's (BRKR) FluoroType SARS-CoV-2 varID Q assay is anticipated to provide reliable detection of the novel Omicron (B.1.1.529) variant of SARS-CoV-2.

Zacks Equity Research

Abbott (ABT) Nutrition Sales Strong Amid Spike in COVID Cases

by Zacks Equity Research

Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

Zacks Equity Research

NEOGEN (NEOG) Strengthens Global Foothold With Delf Buyout

by Zacks Equity Research

NEOGEN (NEOG) management believes that Delf's 40 years of experience in the UK dairy hygiene market will help it strengthen its foothold in this region's dairy chemicals market.

Zacks Equity Research

Walgreens Boots (WBA) Faces Margin Pressure, Solvency Issue

by Zacks Equity Research

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margin significantly.

Zacks Equity Research

Henry Schein (HSIC) Introduces Treatment Planning Software

by Zacks Equity Research

The Studio Pro 4.0 launched by Henry Schein's (HSIC) orthodontics business will enable Reveal Clear Aligners providers to personalize treatment plans with greater ease and control.

Zacks Equity Research

Medtronic (MDT) Gets Health Canada License for GI Genius Module

by Zacks Equity Research

Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.

Zacks Equity Research

Here's Why You Should Invest In Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bruker's (BRKR) better-than-expected results and strong segmental performance.

Zacks Equity Research

QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing

by Zacks Equity Research

QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.

Zacks Equity Research

Here's Why You Should Hold on to Globus Medical (GMED) for Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.

Zacks Equity Research

Here's Why You Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.

Zacks Equity Research

Smith+Nephew (SNN) Introduces Real Intelligence & CORI System

by Zacks Equity Research

Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada.

Zacks Equity Research

Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers

by Zacks Equity Research

Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).

Zacks Equity Research

Medtronic (MDT) Gets CE Mark for Radial Artery Access Portfolio

by Zacks Equity Research

Medtronic's (MDT) Rist Radial Access Catheters are indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.

Zacks Equity Research

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).